CVRX on Nasdaq
CVRx (United States)
Company in Minneapolis, United States.1
Price unavailable
Last updated Oct 16, 2026.
Overview
2001Founded1
Compare with Apyx Medical Corp, Meihua International Medical Technologies Co., Ltd. or LENSAR, Inc., or pick any stock.
Financials
From the company’s reports to the SEC. Every number links to the filing it came from.
Key numbers, fiscal 2025
85.3%Gross margin4
-90.5%Operating margin4
-94.1%Net margin4
10.4%Revenue growth, 20254
-135.6%Return on equity4
1.26×Debt to equity4
-$40.8MFree cash flow4
What sells
Revenue by product, business segment and region, as the company reports it to the SEC.
Regions
United States brought in 92% of the revenue CVRx (United States) broke down this way in fiscal 2025.
Regions by year
| Regions | 2024 | 2025 |
|---|---|---|
| United States | $47.2M | $51.9M |
| Germany | $4.1M | $4.8M |
Where the money goes
Where each dollar of revenue went, fiscal 2025
- Cost of revenue8¢$8.3M
- Research and development10¢$11.1M
- Selling, general and admin82¢$88.5M
- Income tax0¢$18.0K
Out of $56.7M in revenue.4 The company lost money this year.
Financial statements
Every line of the income statement in the latest annual report, as filed.4
| Period ending | 2025-12-31 | 2024-12-31 |
|---|---|---|
| Revenue | $56.7M | $51.3M |
| Cost of goods sold | $8.3M | $8.3M |
| Gross profit | $48.3M | $43.0M |
| Research and development | $11.1M | $11.1M |
| Selling, general and administrative | $88.5M | $91.3M |
| Total operating expenses | $99.6M | $102.4M |
| Loss from operations | -$51.3M | -$59.5M |
| Interest expense | -$5.8M | -$4.4M |
| Other income, net | $3.8M | $4.0M |
| Loss before income taxes | -$53.3M | -$59.9M |
| Benefit (provision) for income taxes | $18.0K | -$55.0K |
| Net loss | -$53.3M | -$60.0M |
| Cumulative translation adjustment | $2.0K | $1.0K |
| Comprehensive loss | -$53.3M | -$60.0M |
| Net loss per share, basic | -$2.04 | -$2.65 |
| Net loss per share, diluted | -$2.04 | -$2.65 |
| Weighted-average common shares used to compute net loss per share, basic | 26.1M shares | 22.6M shares |
| Weighted-average common shares used to compute net loss per share, diluted | 26.1M shares | 22.6M shares |
Every line of the balance sheet in the latest annual report, as filed.4
| Period ending | 2025-12-31 | 2024-12-31 | 2023-12-31 |
|---|---|---|---|
| Cash and cash equivalents | $75.7M | $105.9M | |
| Accounts receivable, net of allowances of $871 and $780, respectively | $10.7M | $9.3M | $7.6M |
| Inventory | $12.2M | $12.1M | |
| Prepaid expenses and other current assets | $3.1M | $2.5M | |
| Total current assets | $101.6M | $129.8M | |
| Property and equipment, net | $2.2M | $2.5M | |
| Operating lease right-of-use asset | $878.0K | $1.1M | |
| Other non-current assets | $26.0K | $27.0K | |
| Total assets | $104.8M | $133.4M | |
| Accounts payable | $3.8M | $2.6M | |
| Accrued expenses | $9.5M | $8.2M | |
| Total current liabilities | $13.3M | $10.8M | |
| Long-term debt | $49.5M | $49.3M | |
| Operating lease liability, non-current portion | $638.0K | $877.0K | |
| Other long-term liabilities | $2.0M | $1.4M | |
| Total liabilities | $65.5M | $62.4M | |
| Common stock, $0.01 par value, 200,000,000 authorized as of December 31, 2025 and 2024; 26,311,607 and 25,324,684 shares issued and outstanding as of December 31, 2025 and 2024, respectively | $263.0K | $253.0K | |
| Additional paid-in capital | $629.9M | $608.4M | |
| Accumulated deficit | -$590.7M | -$537.3M | |
| Accumulated other comprehensive loss | -$203.0K | -$206.0K | |
| Total stockholders' equity | $39.3M | $71.1M | $75.9M |
| Total liabilities and stockholders' equity | $104.8M | $133.4M | |
| Allowance for accounts receivable, net | $871.0K | $780.0K | |
| Common stock, par value (in dollars per share) | $0.01 | $0.01 | |
| Common stock, shares authorized | 200.0M shares | 200.0M shares | |
| Common stock, shares issued | 26.3M shares | 25.3M shares | |
| Common stock, shares outstanding | 26.3M shares | 25.3M shares |
Cash flow is reported year to date, not quarter by quarter, so there are no separate quarterly figures.
Every line of the cash flow in the latest annual report, as filed.4
| Period ending | 2025-12-31 | 2024-12-31 |
|---|---|---|
| Net loss | -$53.3M | -$60.0M |
| Stock-based compensation | $11.1M | $19.1M |
| Depreciation of property and equipment | $756.0K | $619.0K |
| Loss on disposal of equipment | $86.0K | $0 |
| Amortization of deferred financing costs and loan discount | $241.0K | $203.0K |
| Accounts receivable | -$1.4M | -$1.7M |
| Inventory | -$98.0K | -$1.1M |
| Prepaid expenses and other current assets | -$543.0K | $531.0K |
| Accounts payable | $1.3M | $698.0K |
| Accrued expenses | $1.8M | $2.6M |
| Net cash used in operating activities | -$40.2M | -$39.1M |
| Purchase of property and equipment | -$580.0K | -$1.4M |
| Net cash used in investing activities | -$580.0K | -$1.4M |
| Proceeds from the exercise of common stock options | $793.0K | $2.7M |
| Proceeds from Employee Stock Purchase Plan | $753.0K | $803.0K |
| Proceeds from the issuance of common stock | $9.0M | $32.5M |
| Proceeds from debt financing | $0 | $20.0M |
| Debt financing costs | $0 | -$152.0K |
| Net cash provided by financing activities | $10.5M | $55.9M |
| Effect of currency exchange on cash and cash equivalents | $5.0K | -$1.0K |
| Net change in cash and cash equivalents | -$30.2M | $15.4M |
| Cash paid for interest | $5.0M | $3.6M |
Former names
- CVRX INCMay 23, 2003 to Jul 15, 20133
Timeline
- 2001Founded Founded1
Recent filings
- Oct 2, 2026SCHEDULE 13D/A
- Sep 21, 20268-K
- Aug 24, 2026SCHEDULE 13D
- Aug 14, 2026SCHEDULE 13G
- Aug 13, 20264
- Aug 13, 20264
- Aug 11, 20268-K
- Aug 6, 20268-K
- Aug 6, 202610-Q
- Jun 9, 20268-K
- Jun 3, 20268-K
- Jun 3, 20263
- Jun 3, 20264
- Jun 3, 20264
- Jun 3, 20264
Every filing from the last three years, summarized. The full record is on SEC EDGAR.2
Links
- Websitewww.cvrx.com1
- WikidataQ50038324
- SEC EDGARCIK 1235912
Sources
The numbers on this page point here. Each one links to the record it came from.
- 1WikidataCVRx (United States) on Wikidata
- 2
- 3
- 4
- 5
- 6
- 7
- 8
- 9
- 10